No Man’s Land: When Metastatic Breast Cancer Responds Long-Term

Come mid-2026, it will be 11 years since my oncologist asked, “What would you think about being treated as if you were early stage?”

I was sitting in a hospital gown, open to the back, on a chair next to her desk. As always, she looked put together and efficient, her question to me a surprise. My heart gave a jump. I was only six months into my treatment for metastatic breast cancer. I had started from a low of knowing very little about breast cancer outside of you get treatment, it ends, and you go back to your regular life. This is the picture many of us have about breast cancer thanks to the efforts of pink October events and regular articles about breast cancer survivors.

But this isn’t the story for plenty of early-stagers and it is not the story at all for those with metastatic breast cancer.

When she posed that question to me, my mind did a lightening-speed analysis, centered around the faces of my kids and husband, and I answered that I would very much like to be treated as if I were early-stage. Very much indeed.

What did that mean, I asked, because I knew by then that “treating as if early stage” was not the norm. It meant that my team — the oncologist, surgeon and radiation oncologist — would start by proposing this care within the setting of the hospital tumor board, where they would present my case and discuss with their peers. This change in my treatment plan was not a sure thing, despite my team proposing it.

Like so much with cancer, nothing was promised.

Whether it was a hard sell to their larger cancer center community, I don’t know. But I do know that my “as if” treatment started soon after with a lumpectomy followed by a month of breast radiation.

For people diagnosed with actual early stage breast cancer, there would be an end date to their drug therapy too. Maybe a year of Herceptin (trastuzumab), maybe five years of anti-estrogen, something, but always with an end date provided (even if that sometimes changes). But that isn’t the way with metastatic breast cancer.

I have remained on Herceptin, which targets the HER2 protein, through all the years since. Hitting the oncology center reliably every three weeks for an IV infusion of the drug that has saved my life. I am part of a small population of people with metastatic breast cancer who are living longer. This is happening because we have more treatments and we have better treatments. Within this population, and even in the narrower HER2-positive metastatic breast cancer segment, it is not the norm to remain on one line of treatment for so long, without cancer progression.

It is a strange place to reside. Many of my friends live with metastatic breast cancer but they are not on the same path I am, at least at the moment. They are on a well-worn path with progression, treatment changes, worsening quality of life, hospice and too often death that comes too soon. My early-stage friends keep a watchful eye on their symptoms and follow-through on what their docs advise, but most of their worries are not mine.

It’s a no man’s land here. No name fits correctly, none reflect the reality of having a disease that could mutate at any moment, causing treatment to stop working, while also honoring the gratitude I have for my continued response. The research isn’t done to know if I could safely stop treatment, though it is underway.

And anyway “know” is too strong a word. Cancer remains a guessing game, too often a game of risks and benefits and choices without clear answers. Some like me have stopped treatment only to have progression, while others stop and do well for years. Which would I be? And what would it be like to use the word “cure” correctly — not cured for this year or no evidence of disease for five? Where cancer is behind me?

This piece reflects the author’s personal experience and perspective. For medical advice, please consult your health care provider.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.